FDA: Page


  • Teva, Allergan sell off more drugs in quest for approval of generics deal

    Mayne Pharma, an Australian company, will pay $652 million for 42 generic drugs currently held by the two companies. 

    By • June 29, 2016
  • In narrow vote, FDA panel supports heart benefit claim for Lilly diabetes drug

    Allowing Boehringer and Lilly to claim Jardiance cuts the risk of cardiac death is expected to significantly boost the drug's market potential. 

    By Ned Pagliarulo • June 29, 2016
  • Gilead wins FDA nod for pan-genotypic Hep C drug

    In an unusual move, Gilead priced Epclusa below the cost of existing drugs Harvoni and Sovaldi, at just under $75,000 for a 12-week course of treatment. 

    By Ned Pagliarulo • June 28, 2016
  • Bristol-Myers eyes new indication as Opdivo nabs breakthrough tag in bladder cancer

    If approved, Opdivo would face tough competition from Roche's bladder cancer drug Tecentriq, which cleared regulatory review in May.   

    By • June 28, 2016
  • FDA halts testing of Regulus' Hep C drug, sending shares into tailspin

    Clinical development was stopped after a second serious adverse event of jaundice was reported. 

    By Ned Pagliarulo • June 27, 2016
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    FDA should be independent agency, former commissioners say

    Speaking at the Spotlight Health conference, six former agency heads called for the FDA to be elevated to Cabinet level.

    By • June 26, 2016
  • Brexit vote creates new uncertainty for UK, EU pharma industry

    Surprising markets, the British people voted Thursday to leave the European Union by a margin of 52% to 48%, creating "immediate challenges" to existing regulatory and trade frameworks. 

    By Ned Pagliarulo • June 24, 2016
  • NIH turns down request to override cancer drug patent

    Consumer groups had argued the $129,000 price tag for Xtandi limits patient access, justifying intervention by the government under a little-used law.

    By Ned Pagliarulo • June 20, 2016
  • NICE greenlights Bristol-Myers' combo drug for melanoma

    A day earlier the U.K. cost agency had denied coverage for a melanoma combination treatment from Roche. 

    By • June 20, 2016
  • Hologic's Zika test can be used on emergency basis, FDA says

    A number of other diagnostics have received similar authorizations in the U.S., as health authorities attempt to screen and test for the mosquito-borne virus. 

    By • June 20, 2016
  • Former FDA official, 3 others charged in insider trading probe

    One of the defendants made roughly $32 million through trades based on tips about pending FDA drug approvals, the SEC alleges. 

    By • June 16, 2016
  • Success rate for clinical trials climbed in recent years: study

    Research published in Nature showed an 11.6% likelihood of drugs moving from Phase 1 to launch, higher than another study recently conducted by BIO. 

    By • June 15, 2016
  • Marathon Pharma latest company to try for approval of Duchenne drug

    Marathon has submitted a new drug application for an older off-patent steroid, unlike previous developmental drugs from BioMarin or Sarepta.

    By Ned Pagliarulo • June 15, 2016
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    FDA warns of kidney risks for diabetes drugs from Janssen, AstraZeneca

    Invokana and Farxiga, along with two other related drugs, will now carry strengthened warnings cautioning of the risk of acute kidney injury. 

    By Ned Pagliarulo • June 14, 2016
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    FDA approves world's first single-dose cholera vaccine

    PaxVax Bermuda's Vaxchora is also the first approved single-dose vaccine for the prevention of cholera in the world. 

    By • June 12, 2016
  • Drugmakers plan stronger pushback on state-level price regulation

    The efforts include a rapid response shop in Washington.

    By • June 10, 2016
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    FDA wants to suspend more than 4,000 illegal Rx sites

    U.S. consumers have purchased unapproved medications from international sellers to treat depression, narcolepsy, glaucoma and other medical conditions. 

    By • June 10, 2016
  • FDA advisory panel backs Teva opioid painkiller

    The panel voted 14-3 on Tuesday to recommend Valentra ER.

    By • June 8, 2016
  • FDA approves Allergan's fixed-dose combo for hyertension

    Byvalson combines the beta blocker, nebivolol (5 mg) and the angiotensin II receptor blocker (80 mg).

    By • June 8, 2016
  • FDA asks Sarepta for more data on muscular dystrophy drug

    Shares of Sarepta jumped 25% higher in late trading Monday, as investors continue to hope for a path to approval for eteplirsen. 

    By Ned Pagliarulo • June 7, 2016
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis cancer drug wins expanded indication in Europe

    Although Afinitor brought in $1.6 billion last year, sales have dipped as the drug faces stiffer competition.

    By • June 2, 2016
  • FDA approves liquid biopsy test from Roche

    The new diagnostic can detect the presence of EGFR gene mutations in lung cancer patients. 

    By • June 2, 2016
  • FDA warns another Indian API supplier on manufacturing lapses

    Violations included an admission from an analyst at Megafine Pharma of falsifying stability testing data. 

    By Ned Pagliarulo • June 1, 2016
  • BioMarin ends Duchenne program, withdraws EU application for drisapersen

    The decision brings BioMarin's current Duchenne program to a close, two years after the company paid $680 million to acquire Prosensa for rights to drisapersen.

    By Ned Pagliarulo • May 31, 2016
  • FDA knocks back Teva drug for Huntingon's, requests more information

    Teva acquired the drug as part of its $3.2 billion deal for Auspex Pharma last year. 

    By • May 31, 2016